Estrella Immunopharma, Inc. financial data

Symbol
ESLA, ESLAW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5858 Horton Street, Suite 370, Emeryville, CA
Fiscal year end
June 30
Former names
TradeUP Acquisition Corp. (to 9/20/2023)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 668 %
Debt-to-equity 16.4 %
Return On Equity -156 % -191%
Return On Assets -134 % -125%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares
Common Stock, Shares, Outstanding 36.6M shares +3643%
Entity Public Float 40.3M USD
Common Stock, Value, Issued 3.66K USD +4.01%
Weighted Average Number of Shares Outstanding, Basic 36.2M shares +3340%
Weighted Average Number of Shares Outstanding, Diluted 36.2M shares +3340%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.45M USD -22.5%
General and Administrative Expense 2.36M USD +33.6%
Operating Income (Loss) -8.82M USD -17%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.38M USD -80.5%
Income Tax Expense (Benefit) 121K USD
Net Income (Loss) Attributable to Parent -8.82M USD -18.5%
Earnings Per Share, Basic 1.42 USD/shares +94.9%
Earnings Per Share, Diluted 1.42 USD/shares +94.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.8M USD -91.9%
Accounts Receivable, after Allowance for Credit Loss, Current 273K USD
Assets, Current 2.24M USD
Operating Lease, Right-of-Use Asset 0 USD
Assets 3.74M USD -86.3%
Accrued Liabilities, Current 167K USD
Liabilities, Current 2.99M USD -82.7%
Deferred Income Tax Liabilities, Net 8.37K USD
Other Liabilities, Noncurrent 12.7K USD
Liabilities 2.99M USD -82.7%
Retained Earnings (Accumulated Deficit) -22.9M USD -62.7%
Stockholders' Equity Attributable to Parent 746K USD -92.6%
Liabilities and Equity 3.74M USD -86.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.22M USD -706%
Net Cash Provided by (Used in) Financing Activities -150K USD -101%
Net Cash Provided by (Used in) Investing Activities -112K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 36.6M shares +4.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4K USD +92.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.8M USD -91.9%
Deferred Tax Assets, Valuation Allowance 4.48M USD +75%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 4.48M USD +75%
Deferred Income Tax Expense (Benefit) -21.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.84M USD +418%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 24.1M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 113K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 0 USD -100%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%